CATALOGO DEI PRODOTTI DELLA RICERCA

CAMINATI, Marco
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.736
EU - Europa 6.397
AS - Asia 5.754
SA - Sud America 858
AF - Africa 218
OC - Oceania 8
Continente sconosciuto - Info sul continente non disponibili 6
Totale 19.977
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.569
RU - Federazione Russa 3.311
SG - Singapore 2.594
CN - Cina 1.290
IT - Italia 991
BR - Brasile 657
VN - Vietnam 607
HK - Hong Kong 561
GB - Regno Unito 449
FR - Francia 343
DE - Germania 332
IE - Irlanda 295
SE - Svezia 261
KR - Corea 176
FI - Finlandia 122
IN - India 112
CA - Canada 81
JP - Giappone 76
AR - Argentina 70
MX - Messico 59
BD - Bangladesh 58
NL - Olanda 55
ID - Indonesia 51
ES - Italia 46
ZA - Sudafrica 46
PL - Polonia 45
NG - Nigeria 41
TR - Turchia 40
BJ - Benin 37
IQ - Iraq 37
TG - Togo 37
CO - Colombia 30
UA - Ucraina 30
AT - Austria 28
EC - Ecuador 25
VE - Venezuela 25
SA - Arabia Saudita 22
BE - Belgio 19
CL - Cile 18
PK - Pakistan 18
MA - Marocco 14
UZ - Uzbekistan 14
PY - Paraguay 13
LT - Lituania 12
JO - Giordania 11
AZ - Azerbaigian 10
PH - Filippine 10
KE - Kenya 9
NO - Norvegia 8
NP - Nepal 8
PE - Perù 8
AE - Emirati Arabi Uniti 7
CH - Svizzera 7
CR - Costa Rica 7
MY - Malesia 7
UY - Uruguay 7
AU - Australia 6
BG - Bulgaria 6
EG - Egitto 6
JM - Giamaica 6
LB - Libano 6
IL - Israele 5
AL - Albania 4
CZ - Repubblica Ceca 4
DO - Repubblica Dominicana 4
DZ - Algeria 4
KZ - Kazakistan 4
LV - Lettonia 4
OM - Oman 4
RS - Serbia 4
SN - Senegal 4
BH - Bahrain 3
BO - Bolivia 3
BY - Bielorussia 3
ET - Etiopia 3
GH - Ghana 3
HU - Ungheria 3
RO - Romania 3
TH - Thailandia 3
TT - Trinidad e Tobago 3
XK - ???statistics.table.value.countryCode.XK??? 3
CI - Costa d'Avorio 2
DM - Dominica 2
EU - Europa 2
HN - Honduras 2
HR - Croazia 2
KG - Kirghizistan 2
LK - Sri Lanka 2
LY - Libia 2
MG - Madagascar 2
PT - Portogallo 2
QA - Qatar 2
SK - Slovacchia (Repubblica Slovacca) 2
SR - Suriname 2
SY - Repubblica araba siriana 2
TJ - Tagikistan 2
TL - Timor Orientale 2
TN - Tunisia 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AF - Afghanistan, Repubblica islamica di 1
Totale 19.953
Salva come PNG Salva come JPEG
Città #
Singapore 1.337
Moscow 1.100
Ashburn 1.054
San Jose 891
Dallas 763
Chandler 604
Hong Kong 550
Verona 354
New York 337
The Dalles 308
Beijing 297
Dublin 290
Southend 245
Ho Chi Minh City 185
Los Angeles 146
Hanoi 132
Lawrence 120
Princeton 120
Sindelfingen 102
Wilmington 95
Jacksonville 82
Munich 79
Buffalo 77
Redondo Beach 71
London 67
Tokyo 67
São Paulo 65
Jinan 64
Columbus 62
Milan 62
Helsinki 59
Ann Arbor 56
Council Bluffs 51
Nanjing 49
Hebei 46
Rome 46
Woodbridge 46
Shenyang 44
Guangzhou 43
Redwood City 41
Warsaw 41
Redmond 40
Santa Clara 40
Turku 40
Abuja 38
Cotonou 37
Amsterdam 36
Boardman 36
Lomé 36
Orem 35
Chennai 34
Denver 33
Brooklyn 32
Zhengzhou 32
Johannesburg 31
Bologna 29
Dong Ket 29
Da Nang 28
Seattle 28
Haikou 27
Haiphong 27
Montreal 27
Nuremberg 27
Houston 26
Jakarta 26
Ningbo 26
Poplar 25
Frankfurt am Main 23
San Francisco 23
Tianjin 23
Changsha 22
Toronto 22
Norwalk 21
Stockholm 21
Boston 20
Kent 20
Mumbai 20
Atlanta 19
Rio de Janeiro 19
Taiyuan 18
Mexico City 17
Naples 17
Phoenix 17
Brussels 16
Taizhou 16
Falkenstein 15
Hangzhou 15
Chicago 14
Tashkent 14
Curitiba 13
Lappeenranta 13
Nanchang 13
Querétaro 13
Vienna 13
Ankara 12
Baghdad 12
Jiaxing 12
Lanzhou 12
Manchester 12
Padova 12
Totale 11.622
Salva come PNG Salva come JPEG
Nome #
Dupilumab-induced hypereosinophilia: review of the literature and algorithm proposal for clinical management 434
Fatal asthma; is it still an epidemic? 207
Safety of Biologic Therapies for Severe Asthma: An Analysis of Adverse Reactions Reported in the WHO Pharmacovigilance Database 197
Allergic rhinitis: pharmacotherapy in pregnancy and old age 185
Allergen specific sublingual immunotherapy in children with asthma and allergic rhinitis 181
Asthmatic patients in COVID-19 outbreak: Few cases despite many cases 180
Asthma in a large COVID-19 cohort: Prevalence, features, and determinants of COVID-19 disease severity 175
Drop-out rate among patients treated with omalizumab for severe asthma: Literature review and real-life experience 171
Asthma control in primary care: the results of an observational cross-sectional study in Italy and Spain 169
Adverse reaction to local anaesthetics: Is it always allergy? 168
Allergic sensitization to common pets (cats/dogs) according to different possible modalities of exposure: an Italian Multicenter Study 166
Asthma and anaphylaxis 161
Onset of eosinophilic granulomatosis with polyangiitis in a patient treated with an IL-5 pathway inhibitor for severe asthma 159
Biologics for Eosinophilic Granulomatosis with Polyangiitis: one size does not fit all 155
Clinical response to biologicals for severe asthma: any relevance for sex in different age ranges? 154
Evaluation of asthma control in the pharmacy: an Italian cross-sectional study 153
Asthma under/misdiagnosis in primary care setting: an observational community-based study in Italy 152
Successful switching from mepolizumab to dupilumab in a patient with EGPA in remission phase and persistent nasal polyposis 152
COVID-19 in severe asthmatic patients during ongoing treatment with biologicals targeting type 2 inflammation: Results from a multicenter Italian survey 151
Allergen Immunotherapy Adherence in the Real World: How Bad Is It and How Can It Be Improved? 150
Periostin: The bone and beyond 150
Thunderstorm Asthma: A Critical Appraisal Based on Clinical Practice 149
Importance of Cardiopulmonary Exercise Testing amongst Subjects Recovering from COVID-19 149
Allergy and Sexual Behaviours: an Update 147
Allergen-specific immunotherapy and COVID-19: What happened? 146
Asthma control in severe asthmatics under treatment with omalizumab: A cross-sectional observational study in Italy 146
COVID-19 Vaccination in Patients with Severe Asthma on Biologic Treatment: Safety, Tolerability, and Impact on Disease Control 145
Biologics and global burden of asthma: A worldwide portrait and a call for action 144
Low‑dose anti‑IL 5 treatment in idiopathic hypereosinophilic syndrome: towards a precision medicine approach for remission maintenance 144
Anxiety and Depression Effects During Drug Provocation Test 143
Anaphylaxis and intimate behaviour 143
ALLERGY AND CORONAVIRUS DISEASE (COVID-19) INTERNATIONAL SURVEY: REAL-LIFE DATA FROM THE ALLERGY COMMUNITY DURING THE PANDEMIC 140
New horizons for the treatment of severe, eosinophilic asthma: benralizumab, a novel precision biologic 139
Idiopathic hypereosinophilic syndromes and rare dysimmune conditions associated with hyper-eosinophilia in practice: An innovative multidisciplinary approach 138
Anti-IL-5 and IL-5Ra: Efficacy and Safety of New Therapeutic Strategies in Severe Uncontrolled Asthma 138
Biologics for the Treatment of Allergic Conditions: Eosinophil Disorders 137
[Fractional exhaled nitric oxide measurement during specific inhalation challenge tests] 136
Mepolizumab 100 mg in severe asthmatic patients with EGPA in remission phase 136
Benralizumab Efficacy in Late Non-Responders to Mepolizumab and Variables Associated with Occurrence of Switching: A Real-Word Perspective 135
Relationship between hair shedding and systemic inflammation in COVID-19 pneumonia 135
Anaphylaxis and Coronavirus Disease 2019 vaccine: a danger relationship? 134
The potential role of local pharmacies to assess asthma control: an Italian cross-sectional study 134
Mepolizumab for severe eosinophilic asthma: a real-world snapshot on clinical markers and timing of response 133
Hidden Comorbidities in Asthma: A Perspective for a Personalized Approach 132
Timing of response and long term efficacy of Omalizumab in non-clonal Mast Cell Activation Syndrome: A case series 132
Profiling blood hypereosinophilia in patients on dupilumab treatment for respiratory conditions: a real-life snapshot 131
Incidence and risk factors for subcutaneous immunotherapy anaphylaxis: the optimization of safety 130
COPD prevalence in a north-eastern Italian general population 130
Balancing efficacy against safety in sublingual immunotherapy with inhalant allergens: what is the best approach? 125
What lies beyond Asthma Control Test: Suggestions for clinical practice 122
Adherence to Intranasal Steroids in Chronic Rhinosinusitis with Nasal Polyposis Prior to and during Biologic Therapy: A Neglected Matter 121
Eosinophilic Granulomatosis With Polyangiitis and Cardiac Involvement: A Case Report 121
Trends and determinants of Emergency Room admissions for asthma: A retrospective evaluation in Northeast Italy 121
Uncontrolled Asthma: Unmet Needs in the Management of Patients 120
Omalizumab management beyond clinical trials: the added value of a network model 119
Relevance of TH2 markers in the assessment and therapeutic management of severe allergic asthma: A real-life perspective 118
Different aspects of severe asthma in real life: Role of Staphylococcus aureus enterotoxins and correlation to comorbidities and disease severity 118
Diagnosis, management and therapeutic options for eosinophilic esophagitis 116
Effects of specific allergen immunotherapy on biological markers and clinical parameters in asthmatic children: a controlled-real life study 116
A hierarchical cluster analysis of the psycological impact of the COVID-19 pandemic on Italian severe asthma patients 113
SANI-Severe Asthma Network in Italy: a way forward to monitor severe asthma 113
Asthma management among different specialists: results from a national Italian survey 113
Comment on: Onset of eosinophilic granulomatosis with polyangiitis in a patient treated with an IL-5 pathway inhibitor for severe asthma: reply 113
Profiling severe asthma: Any relevance for age? An analysis from Severe Asthma Network Italy (SANI) cohort 113
Premature aging of the immune system affects the response to SARS-CoV-2 mRNA vaccine in β-Thalassemia: additional dose role 112
Safety of Biological Therapies for Severe Asthma: An Analysis of Suspected Adverse Reactions Reported in the WHO Pharmacovigilance Database 111
Choosing wisely: practical considerations on treatment efficacy and safety of asthma in the elderly 111
Safety of uSCIT-MPL-4: prevalence and risk factors of systemic reactions in real life 111
Low adherence to inhaled corticosteroids/long-acting β2-agonists and biologic treatment in severe asthmatics 111
Relevance of Smoking Habit in Severe Asthma Patients: Evidence from the Severe Asthma Network in Italy (SANI) Registry 110
Oral CorticoSteroid sparing with biologics in severe asthma: A remark of the Severe Asthma Network in Italy (SANI) 110
The pathogenesis, epidemiology and biomarkers of susceptibility of pulmonary fibrosis in COVID-19 survivors 109
Remission in Type 2 Inflammatory Diseases: Current Evidence, Unmet Needs, and Suggestions for Defining Remission in Chronic Rhinosinusitis with Nasal Polyps 109
Aspergillus fumigatus and personalized medicine: Toward a clinically reliable algorithm 108
Severe refractory asthma: current treatment options and ongoing research 108
Efficacy of Benralizumab in severe asthma in real life and focus on nasal polyposis 108
Diagnosis and Management of Allergic Rhinitis in Asthmatic Children 108
Targeting eosinophils: severe asthma and beyond 107
Towards precision medicine: The application of omics technologies in asthma management 106
How far from correct is the use of adrenaline auto-injectors? A survey in Italian patients 106
Higher blood eosinophil levels after omalizumab treatment may be associated with poorer asthma outcomes 104
Epidemiology of the relationship between allergic bronchopulmonary aspergillosis and asthma 104
Extracellular Vesicles in Asthma: Intercellular Cross-Talk in TH2 Inflammation 103
Biologic Therapy in a Patient with Asthma and Nasal Polyps 102
Unlocking the Long-Term Effectiveness of Benralizumab in Severe Eosinophilic Asthma: A Three-Year Real-Life Study 101
Oral health in asthmatic patients: a review: Asthma and its therapy may impact on oral health 101
One-year mepolizumab for Allergic bronchopulmonary aspergillosis: Focus on steroid sparing effect and markers of response 101
Inflammatory and senescence-associated mediators affect the persistence of humoral response to COVID-19 mRNA vaccination in transfusion-dependent beta-thalassemic patients 100
One year of mepolizumab. Efficacy and safety in real-life in Italy 100
Component resolved diagnosis (CRD): how much is it presently used by Italian allergists? 100
Serum periostin during omalizumab therapy in asthma: A tool for patient selection and treatment evaluation 99
Effect of α1 Antitrypsin Deficiency on Lung Volume Decline in Severe Asthmatic Patients Undergoing Biologic Therapy 99
Safety of dupilumab in T2 airways conditions: focus on eosinophilia across trials and real-life evidence 99
Dupilumab Efficacy on Asthma Functional, Inflammatory, and Patient-Reported Outcomes across Different Disease Phenotypes and Severity: A Real-Life Perspective 98
Quality of life in patients with food allergy 98
Italian study on buckwheat allergy: prevalence and clinical features of buckwheat-sensitized patients in Italy 97
Immunoglobulin free light chains in severe asthma patient: Could they be a new biomarker? 97
Sex in Respiratory and Skin Allergies 96
Severe Asthma Network Italy Definition of Clinical Remission in Severe Asthma: A Delphi Consensus 96
Serum biomarkers of remodeling in severe asthma with fixed airway obstruction and the potential role of KL-6 94
Totale 13.132
Salva come PNG Salva come JPEG
Categoria #
all - tutte 73.966
article - articoli 73.708
book - libri 0
conference - conferenze 258
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 147.932
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021108 0 0 0 0 0 0 0 0 0 9 45 54
2021/2022714 94 176 15 43 15 14 7 50 50 12 58 180
2022/20231.926 145 138 223 221 217 452 43 106 240 12 80 49
2023/20241.487 57 102 124 196 117 345 110 61 19 62 194 100
2024/20253.674 177 215 155 507 136 92 115 346 581 266 303 781
2025/202611.102 813 706 774 1.892 2.995 758 1.066 693 873 532 0 0
Totale 20.247